Not independent
Tenure on this board
0.9 yrs
9 nominees · 16 ballot items.
The Amrize Ltd 2026 Annual General Meeting agenda includes 16 proposals covering approval of annual reports and financial statements, advisory Say on Pay votes and remuneration reports, capital distributions and loss offset, discharge of liability, board and committee elections, compensation cap approvals, auditor and Independent Voting Representative appointments.
Approve Amrize's Annual Report for 2025, including the Consolidated Financial Statements and the Statutory Financial Statements.
Advisory, non-binding vote to approve the compensation of Amrize’s Named Executive Officers as disclosed in the Compensation Report for 2025.
Advisory vote on how often Amrize should hold an advisory vote on executive compensation (every 1, 2 or 3 years).
Advisory vote to approve the Swiss Statutory Remuneration Report for 2025.
Advisory vote to approve Amrize’s Non-Financial Matters Report for 2025.
Offset with legal retained earnings and capital reserves to bring forward a balance.
Approve a one-time special distribution of legal reserves from capital contributions up to USD 0.44 per outstanding share.
Approve the annual ordinary distribution of legal reserves from capital contributions up to USD 0.44 per share in up to four installments.
Discharge the Board and Executive Management from liability for actions during 2025.
Board re-election for a one-year term ending at the 2027 AGM; includes re-election of nine directors (10.A.–10.I.).
Re-elect Jan Jenisch as Chairman for a one-year term.
Re-elect the three current Compensation Committee members for a one-year term.
Approve the maximum aggregate compensation for the Board for the period.
Approve the maximum aggregate compensation for the Executive Management for FY2027.
Re-elect Ernst & Young AG as statutory auditors and ratify Ernst & Young LLP as the independent registered public accounting firm for US reporting for 2026.
Elect Advoro Zurich Ltd as Independent Voting Representative for a one-year term.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 3.73% | 20,628,430 | $1.1B |
| 2 | HARRIS ASSOCIATES L P | 1.97% | 10,917,267 | $612M |
| 3 | Zurcher Kantonalbank (Zurich Cantonalbank | 1.93% | 10,681,187 | $579M |
| 4 | BlackRock, Inc. | 1.59% | 8,827,771 | $495M |
| 5 | VANGUARD FIDUCIARY TRUST CO | 1.29% | 7,114,738 | $396M |
| 6 | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 1.28% | 7,094,974 | $397M |
| 7 | UBS Group AG | 1.15% | 6,338,048 | $355M |
| 8 | Pictet Asset Management Holding SA | 0.94% | 5,216,765 | $283M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.93% | 5,125,169 | $286M |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 0.84% | 4,641,301 | $251M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.